Genprex Garners Orphan Drug Designation for Lung Cancer Immunogene Therapy Reqorsa
The new orphan drug designation follows a recently received fast track designation for Reqorsa in combination with Tecentriq for an extensive-stage small cell lung cancer indication.
Genprex’s quaratusugene ozeplasmid (Reqorsa), an investigational immunogene therapy intended to treat various forms of lung cancer, has been granted orphan drug designation by the FDA for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with Genentech's checkpoint inhibitor atezolizumab (Tecentriq) for patients who did not experience tumor progression following initial standard treatment with atezolizumab and chemotherapy.1
Reqorsa
“We are excited to receive orphan drug designation from the FDA for Reqorsa for patients with SCLC,” Rodney Varner, the president, chairman, and chief executive officer of Genprex, said in a statement.1 “This FDA orphan drug designation in combination with our recently received FDA Fast Track designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC and non–small cell lung cancer (NSCLC). We look forward to initiating the Acclaim-3 clinical trial expected in the fourth quarter of 2023 in order to bring hope of an effective new therapy to patients suffering with this life-limiting cancer.”
The initial dose escalation portion planned for Acclaim-3 will enroll as many as 12 patients at up to 5 clinical trial sites in the United States. The phase 2 portion will enroll approximately 50 patients at up to 10 clinical trial sites to be treated at the recommended phase 2 dose. The primary end point for this portion is the 18-week progression-free survival (PFS) rate measured from the initiation of treatment with the maintenance therapy.
Reqorsa has received 3 FTDs from the FDA in total. In addition to the aforementioned FTD for the Reqorsa/atezolizumab combination, FTDs have been granted for 2 combinations aimed at treating NSCLC indications. These include the combination of Reqorsa and epidermal growth factor receptor tyrosine kinase inhibitor osimertinib (Tagrisso; AstraZeneca) in patients whose disease progressed after being treated with osimertinib and the combination of Reqorsa and PD1 antibody pembrolizumab (Keytruda; Merck) in patients whose disease progressed after being treated with Keytruda. The Reqorsa/ozeplasmid combination is currently being evaluated in the phase 1/2
Reqorsa is intended to restore expression of TUSC2, a tumor suppressor gene that has reduced or absent expression in nearly all SCLCs.1 Delivered intravenously, it consists of a plasmid expressing TUSC2 encapsulated in a lipid nanoparticle. Preclinical mouse model research determined that restoring expression of TUSC2 could have a clinical impact.
REFERENCES
1. Genprex granted FDA orphan drug designation (ODD) for REQORSA® immunogene therapy for the treatment of small cell lung cancer. News release. Genprex, Inc. August 10, 2023. Accessed August 15, 2023. https://www.genprex.com/news/genprex-granted-fda-orphan-drug-designation-odd-for-reqorsa-immunogene-therapy-for-the-treatment-of-small-cell-lung-cancer/
2. Genprex receives U.S. FDA fast track designation for REQORSA immunogene therapy in combination with Tecentriq for the treatment of small cell lung cancer. News release. Genprex, Inc. June 28, 2023. Accessed August 15, 2023. https://www.genprex.com/news/genprex-receives-u-s-fda-fast-track-designation-for-reqorsa-immunogene-therapy-in-combination-with-tecentriq-for-the-treatment-of-small-cell-lung-cancer/
3. Genprex receives safety review committee approval to advance to phase 2 expansion portion of Acclaim-1 clinical trial of REQORSA® in combination with Tagrisso in advanced non-small cell lung cancer. News release. Genprex, Inc. May 30, 2023. Accessed August 15, 2023. https://www.genprex.com/news/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-expansion-portion-of-acclaim-1-clinical-trial-of-reqorsa-in-combination-with-tagrisso-in-advanced-non-small-cell-lun/
4. Genprex announces the opening for enrollment of its phase 1/2 Acclaim-2 clinical trial of REQORSA immunogene therapy in combination with Keytruda to treat non-small cell lung cancer. News Release. Genprex Inc. March 31, 2022. Accessed August 15, 2023. https://www.obroncology.com/news/genprex-announces-the-opening-for-enrollment-of-its-phase-1-2-acclaim-2
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025